Novosense(SH:688052)2024-04-25 10:24Financial Performance - The company's operating revenue for Q1 2024 was ¥362,481,635.24, representing a decrease of 23.04% compared to the same period last year[4]. - The net profit attributable to shareholders of the listed company was -¥150,029,219.93, a decline of 9,677.28% year-on-year[4]. - The basic and diluted earnings per share were both -¥1.05, reflecting a significant decline of 5,350.00%[5]. - Net profit for Q1 2024 was a loss of ¥150,029,219.93, compared to a profit of ¥1,566,512.47 in Q1 2023[18]. - The company reported a total comprehensive income of -¥150,153,654.26 for Q1 2024, compared to ¥1,566,512.47 in Q1 2023[19]. - The company's total comprehensive income for Q1 2024 was a loss of approximately ¥122.53 million, compared to a profit of ¥14.70 million in Q1 2023[27]. Cash Flow - The net cash flow from operating activities was ¥12,755,456.56, with no applicable year-on-year comparison[5]. - Cash inflow from operating activities in Q1 2024 was ¥9,035,982.39, significantly lower than ¥63,057,582.34 in Q1 2023[20]. - The net cash flow from operating activities for Q1 2024 was approximately ¥36.14 million, a recovery from a negative cash flow of ¥77.47 million in Q1 2023[29]. - The net cash flow from financing activities was -9,349,263.23 RMB, an improvement from -14,958,723.29 RMB in the previous period[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,024,114,766.58, a decrease of 1.85% from the end of the previous year[5]. - The company's total assets amounted to approximately RMB 7.02 billion, a decrease from RMB 7.16 billion as of December 31, 2023, reflecting a decline of about 1.9%[13][15]. - The total liabilities were reported at 498,527,435.39 RMB, down from 532,107,040.25 RMB[24]. - The company reported a decrease in total liabilities to approximately RMB 897.43 million from RMB 948.79 million, a reduction of about 5.4%[15]. Research and Development - Research and development expenses totaled ¥152,049,258.16, accounting for 41.95% of operating revenue, an increase of 8.25 percentage points year-on-year[5]. - Research and development expenses for Q1 2024 were ¥152,049,258.16, slightly down from ¥158,747,766.35 in Q1 2023[17]. - Research and development expenses for Q1 2024 were approximately ¥142.18 million, down 16.1% from ¥169.47 million in Q1 2023[26]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,365, with the largest shareholder holding 10.87% of the shares[10]. - The company has not reported any significant changes in shareholder participation in margin trading or securities lending activities[12]. Operating Costs - Total operating costs increased to ¥508,014,424.44 in Q1 2024 from ¥489,042,781.87 in Q1 2023, representing a rise of 3.3%[17]. - Sales expenses increased to ¥42,574,389.29 in Q1 2024 from ¥23,271,369.43 in Q1 2023, marking an increase of 83.0%[17]. - Management expenses rose to ¥69,600,907.81 in Q1 2024, compared to ¥51,176,758.29 in Q1 2023, an increase of 36.0%[17]. Other Financial Metrics - Non-recurring gains and losses included a government subsidy of ¥65,093.45 and a fair value change gain of ¥9,259,689.12 from financial assets[6]. - The weighted average return on net assets was -2.43%, a decrease of 2.45 percentage points year-on-year[5]. - The company's cash and cash equivalents increased to approximately RMB 2.72 billion from RMB 1.75 billion, representing a growth of approximately 55.5%[13]. - The company's total equity attributable to shareholders decreased to approximately RMB 6.13 billion from RMB 6.21 billion, a decline of about 1.4%[15].